Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy
Jennifer L. Crombie(Dana-Farber Cancer Institute), Brian Hess(Washington University in St. Louis), Geoffrey Shouse(City Of Hope National Medical Center), Robert Redd(Harvard University), Erin Mullane(University of Washington), Alex F. Herrera(City of Hope), Roch Houot(Inserm), Jonathon B. Cohen(Emory University), Caron A. Jacobson(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Anna Saucier(Dana-Farber Cancer Institute), Jason T. Romancik(Emory University), Victor A. Chow(Whipps Cross University Hospital), Jordan Gauthier(Seattle Cancer Care Alliance)
Cited by 3
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
|Journal of Clinical Oncology|2017|468